Poolbeg Pharma Plc is a clinical-stage biopharmaceutical company, which focuses on the development of innovative medicines to address unmet medical needs. The firm is focused on the development of medicines to address unmet medical needs. Its clinical programmes target addressable markets, including cancer immunotherapy-induced Cytokine Release Syndrome (CRS) and metabolic conditions, such as obesity with the development of an oral encapsulated glucagon-like peptide (GLP-1R) agonist. Its pipeline includes POLB 001 Oncology, POLB 001 Influenza, AI Programmes and Oral Encapsulated GLP-1programme. POLB 001 is an orally delivered p38 MAP Kinase inhibitor being developed for the prevention of CRS associated with Bispecific Antibodies and CAR T immunotherapy treatments in cancer. The company uses artificial intelligence to identify infectious disease drug targets & treatments. The Oral Encapsulated GLP-1 programme leverages an advanced delivery system that encapsulates active pharmaceutical ingredients using Generally Regarded as Safe (GRAS) components.
Follow-Up Questions
Who is the CEO of Poolbeg Pharma PLC?
Dr. Jeremy Skillington is the Chief Executive Officer of Poolbeg Pharma PLC, joining the firm since 2021.
What is the price performance of POLBF stock?
The current price of POLBF is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Poolbeg Pharma PLC?
Poolbeg Pharma PLC belongs to Pharmaceuticals industry and the sector is Health Care
What is Poolbeg Pharma PLC market cap?
Poolbeg Pharma PLC's current market cap is $0
Is Poolbeg Pharma PLC a buy, sell, or hold?
According to wall street analysts, 5 analysts have made analyst ratings for Poolbeg Pharma PLC, including 1 strong buy, 3 buy, 1 hold, 0 sell, and 1 strong sell
